三阴性乳腺癌预后生物标志物研究新进展
New Advances in Prognostic Biomarker of Triple-Negative Breast Cancer
摘要: 三阴性乳腺癌(triple-negative breast cancer, TNBC)与其他乳腺癌亚型相比，化疗是其主要的治疗方式，化疗导致的毒副作用以及耐药性使得TNBC患者的远期预后不容乐观。这种情况进一步鼓励接受生物标志物作为有效和精确的TNBC治疗的一些靶向部分迫在眉睫。在本综述中，我们旨在讨论TNBC以及相关的新兴和已批准疗法中已建立和开发的预后和预测生物标志物的最新进展。
Abstract: Compared with other subtypes of breast cancer, chemotherapy is the main treatment for triple negative breast cancer (TNBC). The long-term prognosis of TNBC patients is not optimistic due to the toxic side effects and drug resistance caused by chemotherapy. This situation further encour-ages the acceptance of biomarkers as effective and precise targeting components for TNBC treat-ment, which is urgent. In this review, we aim to discuss the latest advances in established and de-veloped prognostic and predictive biomarkers in TNBC and related emerging and approved thera-pies.
文章引用：曹钰, 贾存东. 三阴性乳腺癌预后生物标志物研究新进展[J]. 临床医学进展, 2023, 13(11): 17000-17005. https://doi.org/10.12677/ACM.2023.13112381

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Siegel, R.L., Miller, K.D. and Jemal, A. (2019) Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7-34. [Google Scholar] [CrossRef] [PubMed]
[3] Lehmann, B.D., Bauer, J.A., Chen, X., et al. (2011) Identification of Hu-man Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted Therapies. Journal of Clinical Investigation, 121, 2750-2767. [Google Scholar] [CrossRef] 
[4] Jiang, Y.Z., Ma, D., Suo, C., et al. (2019) Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 35, 428-440.e5.
[5] Tomas, A., Futter, C.E. and Eden, E.R. (2014) EGF Receptor Trafficking: Consequences for Signaling and Cancer. Trends in Cell Biology, 24, 26-34. [Google Scholar] [CrossRef] [PubMed]
[6] Corkery, B., Crown, J., Clynes, M., et al. (2009) Epidermal Growth Factor Receptor as a Potential Therapeutic Target in Triple-Negative Breast Cancer. Annals of Oncology, 20, 862-867. [Google Scholar] [CrossRef] [PubMed]
[7] Linderholm, B.K., Hellborg, H., Johansson, U., et al. (2009) Significantly Higher Levels of Vascular Endothelial Growth Factor (VEGF) and Shorter Survival Times for Patients with Primary Operable Triple-Negative Breast Cancer. Annals of Oncology, 20, 1639-1646. [Google Scholar] [CrossRef] [PubMed]
[8] Zhu, X. and Zhou, W. (2015) The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer. Frontiers in Endocrinology, 6, Article No. 159. [Google Scholar] [CrossRef] [PubMed]
[9] Brufsky, A.M., Hurvitz, S., Perez, E., et al. (2011) RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 29, 4286-4293. [Google Scholar] [CrossRef] 
[10] Cameron, D., Brown, J., Dent, R., et al. (2013) Adjuvant Bevaci-zumab-Containing Therapy in Triple-Negative Breast Cancer (BEATRICE): Primary Results of a Randomised, Phase 3 Trial. The Lancet Oncology, 14, 933-942. [Google Scholar] [CrossRef] 
[11] Jahan, N., Jones, C. and Rahman, R.L. (2021) Androgen Receptor Expression in Breast Cancer: Implications on Prognosis and Treatment, a Brief Review. Molecular and Cellular Endocrinology, 531, Article ID: 111324. [Google Scholar] [CrossRef] [PubMed]
[12] Traina, T.A., Miller, K., Yardley, D.A., et al. (2018) Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. Journal of Clinical Oncology, 36, 884-890. [Google Scholar] [CrossRef] 
[13] Borsos, B.N., Páhi, Z.G., Ujfaludi, Z., et al. (2022) BC-miR: Monitoring Breast Cancer-Related miRNA Profile in Blood Sera—A Prosperous Approach for Tumor Detection. Cells, 11, Article No. 2721. [Google Scholar] [CrossRef] [PubMed]
[14] Hong, H.C., Chuang, C.H., Huang, W.C., et al. (2020) A Panel of Eight microRNAs Is a Good Predictive Parameter for Triple-Negative Breast Cancer Relapse. Theranostics, 10, 8771-8789. [Google Scholar] [CrossRef] [PubMed]
[15] Clark, S.L., Rodriguez, A.M., Snyder, R.R., et al. (2012) Structure-Function of the Tumor Suppressor BRCA1. Computational and Structural Biotechnology Journal, 1, e201204005. [Google Scholar] [CrossRef] [PubMed]
[16] Robson, M., Im, S.A., Senkus, E., et al. (2017) Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine, 377, 523-533. [Google Scholar] [CrossRef] 
[17] Duffy, M.J., Synnott, N.C. and Crown, J. (2018) Mutant p53 in Breast Cancer: Potential as a Therapeutic Target and Biomarker. Breast Cancer Research and Treatment, 170, 213-219. [Google Scholar] [CrossRef] [PubMed]
[18] Miricescu, D., Totan, A., Stanescu-Spinu, I.I., et al. (2020) PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. Interna-tional Journal of Molecular Sciences, 22, Article No. 173. [Google Scholar] [CrossRef] [PubMed]
[19] Kim, S.B., Dent, R., Im, S.A., et al. (2017) Ipatasertib plus Paclitaxel versus Placebo plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer (LOTUS): A Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. The Lancet Oncology, 18, 1360-1372. [Google Scholar] [CrossRef] 
[20] Carter, J.M., Polley, M.Y.C., Leon-Ferre, R.A., et al. (2021) Characteristics and Spatially Defined Immune (Micro)landscapes of Early-Stage PD-L1-Positive Triple-Negative Breast Cancer. Clinical Cancer Research, 27, 5628-5637. [Google Scholar] [CrossRef] 
[21] Mittendorf, E.A., Zhang, H., Barrios, C.H., et al. (2020) Neoadjuvant Atezolizumab in Combination with Sequential Nab-Paclitaxel and Anthracycline-Based Chemotherapy ver-sus Placebo and Chemotherapy in Patients with Early-Stage Triple-Negative Breast Cancer (IMpassion031): A Random-ised, Double-Blind, Phase 3 Trial. The Lancet, 396, 1090-1100. [Google Scholar] [CrossRef] 
[22] Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas, P., Virassamy, B., et al. (2018) Single-Cell Profiling of Breast Cancer T Cells Reveals a Tissue-Resident Memory Subset Associated with Improved Prognosis. Nature Medicine, 24, 986-993. [Google Scholar] [CrossRef] [PubMed]
[23] Ibrahim, E.M., Al-Foheidi, M.E., Al-Mansour, M.M., et al. (2014) The Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: A Meta-Analysis. Breast Cancer Research and Treatment, 148, 467-476. [Google Scholar] [CrossRef] [PubMed]
[24] Jaini, R., Kesaraju, P., Johnson, J.M., et al. (2010) An Autoim-mune-Mediated Strategy for Prophylactic Breast Cancer Vaccination. Nature Medicine, 16, 799-803. [Google Scholar] [CrossRef] [PubMed]
[25] Amedei, A., Asadzadeh, F., Papi, F., et al. (2020) A Structurally Simple Vaccine Candidate Reduces Progression and Dissemination of Triple-Negative Breast Cancer. iScience, 23, Article ID: 101250. [Google Scholar] [CrossRef] [PubMed]
[26] Bardia, A., Mayer, I.A., Vahdat, L.T., et al. (2019) Sacituzumab Govitecanhziy in Refractory Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 380, 741-751. [Google Scholar] [CrossRef] 
[27] Bardia, A., Hurvitz, S.A., Tolaney, S.M., et al. (2021) Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 384, 1529-1541. [Google Scholar] [CrossRef] 

为你推荐